Deutsche Bank Maintains PT, Rating On NKTR After In-Line Results

Deutsche Bank is maintaining its Buy rating and its $14 price target on Nektar Therapeutics NKTR based upon the company's in-line Q1 results. According to Deutsche Bank, “With a steadily growing royalty stream from 9 products, 6 programs in late-stage development (1 proprietary, 5 partnered), and a significant early stage pipeline comprised of 9 candidates, Nektar looks increasingly well positioned to participate in a number of potentially lucrative therapeutic markets in the years to come. Hence, we continue to rate Nektar shares Buy.” NKTR closed at $9.96 yesterday.